<DOC>
	<DOC>NCT02259998</DOC>
	<brief_summary>To investigate the relative bioavailability of the proposed formulation of PERSANTIN® compared to the present commercial formulation.</brief_summary>
	<brief_title>Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>All participants in the study should be healthy males, range from 21 to 50 years of age and their body mass index (BMI) be within 18.5 to 29.9 kg/m2 All participants must give their written informed consent in accordance with Good Clinical Practice and local legislation prior to admission to the study Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than 10 halflives of the respective drug before enrolment in the study or during the study Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study Participation in another trial with an investigational drug (&lt;= two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (&gt;= 100 ml within four weeks prior to administration or during the trial) Any laboratory value outside the clinically accepted reference range Excessive physical activities within the last week before the trial or during the trial Following exclusion criteria are of special interest for this study: History of haemorrhagic diathesis History of gastrointestinal ulcer, perforation or bleeding Glucose6phosphatedehydrogenase (G6PD) deficiency</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>